CSPC Pharmaceutical Expands On-Market Buybacks for 2026 Share Award Scheme

TipRanksJun 16 20:32

CSPC Pharma (01093): The marketing authorization application for Valsartan and Levamlodipine Maleate Tablets (SYH 9056 Tablets) has been accepted by the National Medical Products Administration.

CSPC Pharma (01093) announced that the marketing authorization application for its developed product, Valsartan and Levamlodipine Maleate Tablets (SYH 9056 Tablets), has been accepted by the National Medical Products Administration of the People's Republic of China. The indication submitted in this application is for the treatment of mild to moderate primary hypertension inadequately controlled by monotherapy. This product is a single-tablet fixed-dose combination of valsartan and levamlodipine maleate (strength: 80 mg/2.5 mg) and was filed as a Category 2.3 new chemical drug, demonstrating significant clinical therapeutic advantages. To date, this fixed-dose combination has not been marketed either domestically or internationally.

Zhitong FinanceJun 16 18:43

China Galaxy Securities: Innovative Drugs Remain in High Demand as Emerging Pillar Sector Undergoes Strategic Upgrade

New regulations on pharmaceutical sales representatives, introduced alongside anti-corruption measures in the healthcare sector, have taken effect. The threshold for criminal liability for commercial bribery has been lowered, and industry-wide compliance reforms are reshaping the pharmaceutical ecosystem, which is expected to significantly alter the landscape of clinically used drugs.

Zhitong FinanceJun 12 11:43

CSPC PHARMA(1093.HK):1Q RESULTS IN LINE WITH EXPECTATIONS INNOVATIVE PIPELINE CONTINUES TO DELIVER

Jun 11 15:22

HK Stock Market Update | Alphamab Oncology (09966.HK) Rises Over 6% as Phase III Clinical Trial of Ennituo as First-Line Treatment for HER2-Positive Advanced Breast Cancer Meets Primary Endpoint

Alphamab Oncology-B (09966) rose more than 6%. As of this report, it was up 4.22% at HK$6.92, with a trading volume of HK$5.1534 million.

Zhitong FinanceJun 11 09:44

Selected HKEX Announcements | Hesai Group's LiDAR shipments in May surged more than threefold year-over-year; Seazen Holdings' sales reached RMB 5.4 billion year-to-date

① Hesai LiDAR shipments increased by more than threefold year-over-year; which business segments showed strong growth? ② Seazen Development achieved sales of RMB 5.4 billion this year; how has its recent performance been?

cls.cnJun 10 20:44